Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer

Breast Cancer Female Clinical Trial

Official title:

A Randomized Controlled Study to Evaluate the Efficacy and Safety of Endocrine Therapy Plus Chemotherapy Versus Chemotherapy Alone as the Neoadjuvant Therapy in the Treatment of ER-positive, HER2-negative Breast Cancer (IIa-IIIc)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02980965
• Other study ID #: NCET-trial
• Status: Completed
• Phase: Phase 3
• First received: November 26, 2016
• Last updated: November 8, 2017
• Start date: May 2013
• Est. completion date: February 2017

Study information

• Verified date: November 2017
• Source: Fudan University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This was an open-label, randomized controlled trial that aims to compare the efficacy and safety of the concurrent neoadjuvant chemotherapy with endocrine therapy and neoadjuvant chemotherapy alone in ER-positive, HER2-negative breast cancer.

Description:

Data showed that concurrent neoadjuvant chemotherapy with endocrine therapy was a effective option for ER-positive, HER2-negative breast cancer patients. However this is still a controversial issue. The present study is an open-label randomized controlled clinical trial that aims to investigate the efficacy of concurrent NCT with endocrine therapy (AI with or without GnRH-a) in patients with ER-positive, HER2-negative breast carcinoma.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 249
• Est. completion date: February 2017
• Est. primary completion date: February 2017
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Estrogen receptor-positive and HER2-negative breast cancer patients, with histological stage of IIa-IIIc.

2. Without previous chemotherapy or endocrine therapy.

3. ECOG scores of 0-2 points

4. With measurable and evaluable breast tumor pathologically confirmed as invasive ductal carcinoma

5. Age: 18-70 years

6. Lateral breast cancer

7. Normal or acceptable kidney, liver, cardiovascular, and bone marrow functions

Exclusion Criteria:

1. Pregnant women or nursing mothers

2. With distant metastasis

3. With a history of malignant tumor or complicated with other malignant tumors in addition to breast cancer, except for non-melanoma skin cancer, in situ cervical cancer or other cured malignant tumor without the basis of recurrence for at least five years

4. With mental illness or other conditions affecting the patient compliance

5. With other serious diseases or medical conditions:

1. Congestive heart failure or unstable angina pectoris, myocardial infarction within 6 months before the enrollment, uncontrolled hypertension and uncontrolled high-risk arrhythmia considered by the investigator

2. Obvious neurological or psychiatric disorders, including psychosis, epileptic dementia and other diseases may affect the understanding and sign of the informed consent for

3. Uncontrolled acute infection

6. Concurrent use of other investigational drugs; or participating in other clinical trials involving investigational drugs within 30 days before this study

7. With allergic constitution and any known or suspected drug allergy

8. Not suitable for the trial considered by the investigator

Related Conditions & MeSH terms

• Breast Cancer Female
• Breast Neoplasms

Intervention

Drug:
• letrozole, leuprorelin, fluorouracil, epirubicin, cyclophosphamide, docetaxel
Postmenopausal patients were treated with letrozole 2.5mg/day p.o until complement of neoadjuvant chemotherapy before surgery, while premenopausal ones received letrozole 2.5mg/day p.o and a subcutaneous injection of the GnRH-a, leuprorelin, as concomitant treatment with neoadjuvant chemotherapy (fluorouracil 600mg/m2 IV, epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles followed by docetaxel 100mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles; or epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles, followed by docetaxel 80mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles), letrozole was delivered after 1 week of first dose of leuprorelin injection.
• fluorouracil, epirubicin, cyclophosphamide, docetaxel
Patients received fluorouracil 500mg/m2 IV, epirubicin 90mg/m2 IV and cyclophosphamide 500mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles followed by docetaxel 100mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles; or epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles, followed by docetaxel 100mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles.

Locations

Country	Name	City	State
China	Cancer Hospital/ Institute, Fudan University	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Fudan University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	objective response rate (ORR)	the proportion of patients achieving clinical complete response and partial response in the breast based on magnetic resonance imaging	4 years
Secondary	Ki67 proliferation marker changes	Absolute Ki67 change as well as geometric mean percentage change in Ki67 positivity	4 years
Secondary	pathologic complete response (pCR)	Disappearance of residual invasive disease (residual ductal carcinoma in situ allowed) in breast and the absence of positive lymph nodes	4 years
Secondary	pathological response rate	The proportion of patients achieving pathological response based on Miller-Payne grading system	4 years
Secondary	Progression-free survival (DFS)	The interval between the date of randomization to disease progression during treatment, any recurrence, contralateral breast cancer, the appearance of a second primary cancer, or death not due to cancer, whichever occurred first.	6 years
Secondary	Incidence of Serious Treatment-Emergent Adverse Events(grade 3 or 4)	Assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0.	4 years